The maker of Tylenol is being sold to Kimberly-Clark in a $48.7 billion deal weeks after President Donald Trump and Health Secretary Robert F Kennedy Jr targeted the drug.
Kimberly-Clark’s purchase of drug maker Kenvue will create a massive consumer health goods company.
Shareholders of Kimberly-Clark will own about 54% of the combined company while Kenvue shareholders will own about 46%.
The combined company will have a large stable of household brands under one roof, putting Kenvue’s Listerine mouthwash and Band-Aid side-by-side with Kimberly-Clark’s Cottonelle toilet paper, Huggies and Kleenex tissues. It will also generate about $32 billion in annual revenue.
Kenvue has spent a relatively brief period as an independent company, having been spun off by Johnson & Johnson two years ago.
J&J first announced in late 2021 that it was splitting its consumer health division from the pharmaceutical and medical device divisions.
The deal announced Monday is among the largest corporate takeovers of the year.
Kenvue was thrust into the national spotlight last month when RFK Jr reasserted the unproven link between the pain reliever Tylenol and autism, and suggested people who opposed the theory were motivated by hatred for Trump.
During a meeting with Trump and the Cabinet, Kennedy reiterated the connection, even while noting there was no medical proof to substantiate the claim.
In July, Kenvue announced that CEO Thibaut Mongon was leaving in the midst of a strategic review with the company under mounting pressure from activist investors. Board member Kirk Perry is serving as interim CEO.
“We will serve billions of consumers across every stage of life,” Kimberly-Clark Chairman and CEO Mike Hsu said in a statement.
Hsu will be chairman and CEO of the combined company. Three members of the Kenvue's board will join Kimberly-Clark's board at closing. The combined company will keep Kimberly-Clark’s headquarters in Irving, Texas and continue to have a significant presence in Kenvue’s locations.
The deal is expected to close in the second half of next year. It still needs approval from shareholders of both both companies.
Kenvue shareholders will receive $3.50 per share in cash and 0.14625 Kimberly-Clark shares for each Kenvue share held at closing. That amounts to $21.01 per share, based on the closing price of Kimberly-Clark shares on Friday.
Kimberly-Clark and Kenvue said that they identified about $1.9 billion in cost savings that are expected in the first three years after the transaction’s closing.
Shares of Kimberly-Clark slipped more than 15% before the market open, while Kenvue's stock jumped more than 20%.
Trump’s comments on Mamdani take a weird turn into appearance
‘On it!’ Trump vows to help cancer-stricken Dilbert creator after public plea
Trump says it’s ‘terrible’ that Andrew lost royal titles over Epstein scandal
Chipotle demand is cratering as Gen Z struggle to make ends meet
Claims of cover up after mysterious object crashed outside of Area 51
Trump ramps up filibuster pressure as shutdown threatens to become longest ever: Live
